Saturday, October 31, 2026

John Wick 4 Breaks the Box Office

John Wick 4 Breaks the Box Office

After a four-year wait, the latest John Wick movie starring Keanu Reeves has finally arrived in theaters. It's the longest gap between movies in the franchise, and it may be the biggest one yet.

Like many recent titles, John Wick: Chapter 4 suffered several delays due to the lockdowns and to avoid competing with titles such as last year's mega-blockbuster Top Gun: Maverick and Reeves' own The Matrix Resurrections.

https://www.youtube.com/embed/Md0kX3UYVEw

Audiences are starved for John Wick's return to the big screens as Chapter 4 managed to gross 73,5 million domestically and 137,5 million internationally over the weekend, all the best figures of the series thus far.

It helps that Chapter 4 has registered 95% of positive reviews on Rotten Tomatoes, also a series best. John Wick is the rare film franchise where each subsequent entry is better received and gets better returns than the previous one, which certainly helps its popularity and staying power.

The sudden passing of Lance Reddick, a beloved mainstay of the series, has overshadowed the success of the Chapter 4 release. Reddick participated in the press tour with no signs that something was wrong, setting a somber tone for the tour.

John Wick: Chapter 5 was initially filmed back-to-back with Chapter 4, but Lionsgate decided to delay it and focus on the fourth installment instead. It is, however, already deep into development.

Two other spin-offs have been completed and are coming soon: Ballerina, about a character introduced in Chapter 3 - Parabellum and starring Ana de Armas, and The Continental, a TV show set before the movies starring Mel Gibson.

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com